Answers are grounded in this paper and cite their sources.
Background Exercise may support skeletal development during childhood and adolescence, but its effects on bone mineral density (BMD) and content (BMC) remain uncertain. This review evaluated structured exercise interventions and explored variation by skeletal site, maturation and programme characteristics. Methods PubMed, Web of Science Core Collection, Embase, CENTRAL and Scopus were searched from inception to 26 September 2026 for randomised trials involving participants younger than 18 years. English-language, peer-reviewed full-text reports were eligible. DXA-derived BMD and BMC were analysed separately using change-score-standardised Hedges’ g and multilevel random-effects models with trial-level CR2 inference and small-sample corrections. Variance calculations accounted for cluster randomisation and paired twin data. Change-score SDs for 30 of 49 primary estimates used assumed baseline–follow-up correlations informed by a meta-analysis in postmenopausal women; sensitivity analyses varied correlations from 0.30 to 0.95 and examined standardisation, risk of bias and design eligibility. Moderator analyses were exploratory. Certainty was assessed using GRADE. Results Primary analyses included 17 BMD estimates from eight trials and 32 BMC estimates from twelve trials. The BMD effect was uncertain (g = 0.073, 95% CI − 0.191 to 0.336; p = 0.525), whereas BMC showed a small positive effect (g = 0.179, 95% CI 0.037 to 0.322; p = 0.019). Alternative correlation assumptions and baseline standardisation retained the statistical interpretation. Including trials with limited cluster replication weakened the BMC result (g = 0.123, 95% CI − 0.048 to 0.294). No clear moderator associations were identified for skeletal site, pubertal stage, exercise category, duration or weekly frequency. Certainty was low for both outcomes because of risk of bias and imprecision. Conclusions Under the primary analytical specifications, structured exercise may offer a small average BMC benefit, while its effect on BMD remains uncertain. Low-certainty evidence, sensitivity to design eligibility and inconclusive moderator analyses limit exercise-prescription recommendations. Further trials should establish the durability and clinical relevance of skeletal changes. Registration PROSPERO CRD420261435125 registered on 28 June 2026, after completion of the initial searches. Clinical trial number Not applicable.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: